315 related articles for article (PubMed ID: 28646657)
1. "Half-sandwich" Schiff-base Ir(III) complexes as anticancer agents.
Mou ZD; Deng N; Zhang F; Zhang J; Cen J; Zhang X
Eur J Med Chem; 2017 Sep; 138():72-82. PubMed ID: 28646657
[TBL] [Abstract][Full Text] [Related]
2. Cyclometalated iridium(III)-guanidinium complexes as mitochondria-targeted anticancer agents.
Song XD; Kong X; He SF; Chen JX; Sun J; Chen BB; Zhao JW; Mao ZW
Eur J Med Chem; 2017 Sep; 138():246-254. PubMed ID: 28668477
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of new salicylaldehyde-2-picolinylhydrazone Schiff base compounds of Ru(II), Rh(III) and Ir(III) as in vitro antitumor, antibacterial and fluorescence imaging agents.
Palepu NR; Nongbri SL; Premkumar JR; Verma AK; Bhattacharjee K; Joshi SR; Forbes S; Mozharivskyj Y; Thounaojam R; Aguan K; Kollipara MR
J Biol Inorg Chem; 2015 Jun; 20(4):619-38. PubMed ID: 25712889
[TBL] [Abstract][Full Text] [Related]
4. Copper complexes based on chiral Schiff-base ligands: DNA/BSA binding ability, DNA cleavage activity, cytotoxicity and mechanism of apoptosis.
Zhou XQ; Li Y; Zhang DY; Nie Y; Li ZJ; Gu W; Liu X; Tian JL; Yan SP
Eur J Med Chem; 2016 May; 114():244-56. PubMed ID: 26994692
[TBL] [Abstract][Full Text] [Related]
5. Biological activity of neutral and cationic iridium(III) complexes with κP and κP,κS coordinated Ph₂PCH₂S(O)xPh (x = 0-2) ligands.
Ludwig G; Mijatović S; Ranđelović I; Bulatović M; Miljković D; Maksimović-Ivanić D; Korb M; Lang H; Steinborn D; Kaluđerović GN
Eur J Med Chem; 2013 Nov; 69():216-22. PubMed ID: 24042044
[TBL] [Abstract][Full Text] [Related]
6. Half-Sandwich Iridium and Ruthenium Complexes: Effective Tracking in Cells and Anticancer Studies.
Li J; Guo L; Tian Z; Zhang S; Xu Z; Han Y; Li R; Li Y; Liu Z
Inorg Chem; 2018 Nov; 57(21):13552-13563. PubMed ID: 30289251
[TBL] [Abstract][Full Text] [Related]
7. Fluorescent iridium(iii) coumarin-salicylaldehyde Schiff base compounds as lysosome-targeted antitumor agents.
Liu C; Liu X; Ge X; Wang Q; Zhang L; Shang W; Zhang Y; Yuan XA; Tian L; Liu Z; You J
Dalton Trans; 2020 May; 49(18):5988-5998. PubMed ID: 32314774
[TBL] [Abstract][Full Text] [Related]
8. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents.
Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z
Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192
[TBL] [Abstract][Full Text] [Related]
9. An iridium (III) complex as potent anticancer agent induces apoptosis and autophagy in B16 cells through inhibition of the AKT/mTOR pathway.
Tang B; Wan D; Wang YJ; Yi QY; Guo BH; Liu YJ
Eur J Med Chem; 2018 Feb; 145():302-314. PubMed ID: 29331753
[TBL] [Abstract][Full Text] [Related]
10. Thiabendazole-based Rh(III) and Ir(III) biscyclometallated complexes with mitochondria-targeted anticancer activity and metal-sensitive photodynamic activity.
Pérez-Arnaiz C; Acuña MI; Busto N; Echevarría I; Martínez-Alonso M; Espino G; García B; Domínguez F
Eur J Med Chem; 2018 Sep; 157():279-293. PubMed ID: 30099251
[TBL] [Abstract][Full Text] [Related]
11. Phenolate based metallomacrocyclic xanthate complexes of Co(II)/Cu(II) and their exclusive deployment in [2 : 2] binuclear N,O-Schiff base macrocycle formation and in vitro anticancer studies.
Singh VK; Kadu R; Roy H; Raghavaiah P; Mobin SM
Dalton Trans; 2016 Jan; 45(4):1443-54. PubMed ID: 26674056
[TBL] [Abstract][Full Text] [Related]
12. High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
Zhao F; Wang W; Lu W; Xu L; Yang S; Cai XM; Zhou M; Lei M; Ma M; Xu HJ; Cao F
Eur J Med Chem; 2018 Feb; 146():451-459. PubMed ID: 29407970
[TBL] [Abstract][Full Text] [Related]
13. Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents.
Yang Y; Guo L; Tian Z; Gong Y; Zheng H; Zhang S; Xu Z; Ge X; Liu Z
Inorg Chem; 2018 Sep; 57(17):11087-11098. PubMed ID: 30133276
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of anticancer effect in vitro and in vivo of iridium(III) complexes on gastric carcinoma SGC-7901 cells.
Zhang WY; Wang YJ; Du F; He M; Gu YY; Bai L; Yang LL; Liu YJ
Eur J Med Chem; 2019 Sep; 178():401-416. PubMed ID: 31202128
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, structural characterization, and anticancer activity of a monobenzyltin compound against MCF-7 breast cancer cells.
Fani S; Kamalidehghan B; Lo KM; Hashim NM; Chow KM; Ahmadipour F
Drug Des Devel Ther; 2015; 9():6191-201. PubMed ID: 26648695
[TBL] [Abstract][Full Text] [Related]
16. Anticancer and antibacterial activity in vitro evaluation of iridium(III) polypyridyl complexes.
Yi QY; Zhang WY; He M; Du F; Wang XZ; Wang YJ; Gu YY; Bai L; Liu YJ
J Biol Inorg Chem; 2019 Mar; 24(2):151-169. PubMed ID: 30564887
[TBL] [Abstract][Full Text] [Related]
17. Lysosome-targeted chemotherapeutics: Anticancer mechanism of N-heterocyclic carbene iridium(III) complex.
Zhang J; Liu J; Liu X; Liu B; Song S; He X; Che C; Si M; Yang G; Liu Z
J Inorg Biochem; 2020 Jun; 207():111063. PubMed ID: 32222581
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of iridium(III) complexes as potential antitumor agents.
Du F; Bai L; He M; Zhang WY; Gu YY; Yin H; Liu YJ
J Inorg Biochem; 2019 Dec; 201():110822. PubMed ID: 31536949
[TBL] [Abstract][Full Text] [Related]
19. Studies of anticancer activity in vitro and in vivo of iridium(III) polypyridyl complexes-loaded liposomes as drug delivery system.
Zhang WY; Du F; He M; Bai L; Gu YY; Yang LL; Liu YJ
Eur J Med Chem; 2019 Sep; 178():390-400. PubMed ID: 31202127
[TBL] [Abstract][Full Text] [Related]
20. Mitochondria-targeted phosphorescent cyclometalated iridium(III) complexes: synthesis, characterization, and anticancer properties.
Li Y; Liu B; Xu CX; He L; Wan YC; Ji LN; Mao ZW
J Biol Inorg Chem; 2020 Jun; 25(4):597-607. PubMed ID: 32232583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
